PT-141 (Bremelanotide) · Research brief

PT-141 vs Bremelanotide — What’s the Difference?

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

60 WORDS

Short answer

Key takeaways

PT-141 and bremelanotide are the exact same melanocortin receptor agonist peptide. The name difference reflects research designation versus pharmaceutical branding, not molecular variation.
Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women at a fixed 1.75mg dose; PT-141 is the research-grade form supplied by compounding facilities without FDA approval.
The peptide acts centrally via MC3R and MC4R receptors in the hypothalamus, modulating desire pathways independently of vascular mechanisms like PDE5 inhibitors.
Research-grade PT-141 costs $8–$15 per 1.75mg dose versus $950+ for branded Vyleesi, with the price gap driven by regulatory approval costs and delivery system differences, not molecular quality.
Both forms degrade irreversibly if stored above 8°C. Lyophilised PT-141 remains stable at −20°C for 24+ months but must be refrigerated after reconstitution and used within 28 days.
HPLC purity for research PT-141 is typically 97–98% versus ≥99% for FDA-approved bremelanotide. A difference that is pharmacologically negligible for MC4R binding affinity.

PT-141 vs Bremelanotide — What's the Difference?

PT-141 and bremelanotide are the exact same synthetic peptide. The cyclic heptapeptide that acts as a melanocortin receptor agonist with selective activity at MC3R and MC4R. The name divergence occurred in 2004 when Palatin Technologies transitioned the compound from Phase II clinical trials (where it was designated PT-141) to Phase III registration trials under the International Nonproprietary Name (INN) bremelanotide. The molecule itself. The seven-amino-acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Never changed. What changed was regulatory status, branding strategy, and eventually FDA approval in 2019 under the trade name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Our team at Real Peptides has synthesised PT-141 for research applications since 2018. The naming confusion creates sourcing errors we see consistently. Researchers assume PT-141 and bremelanotide represent different compounds with distinct pharmacological profiles, when in reality they're purchasing the same molecule under two commercial designations.

What's the difference between PT-141 and bremelanotide?

PT-141 and bremelanotide are identical. The same melanocortin receptor agonist peptide with no molecular variation. PT-141 is the original research code used during preclinical and early-phase clinical development; bremelanotide is the INN assigned when the compound advanced to Phase III trials and eventual FDA approval. The only substantive difference is regulatory classification: bremelanotide (Vyleesi) is FDA-approved as a prescription drug for HSDD, while PT-141 remains the designation used for non-approved research-grade material supplied by compounding facilities and peptide research suppliers.

The Featured Snippet gives you the regulatory distinction. Here's the practical implication most sources skip. When you order PT-141 from a research supplier, you're receiving the same active peptide as branded Vyleesi, but without FDA batch-level oversight, without the pre-filled autoinjector delivery system, and at 70–85% lower cost per dose. The molecule is identical; the quality assurance infrastructure is not. Compounded PT-141 is synthesised by 503B facilities or sourced from international peptide manufacturers, then tested via HPLC and mass spectrometry for purity verification. But those tests are performed by the supplier, not by the FDA. This article covers the pharmacological mechanism both names describe, the sourcing and regulatory differences that create the price gap, and what preparation mistakes compromise peptide integrity before the first dose.

The Melanocortin Receptor Mechanism Both Names Describe

PT-141 (bremelanotide) works by binding to melanocortin receptors MC3R and MC4R in the central nervous system, primarily the hypothalamus and limbic system. These receptors modulate sexual arousal pathways independently of vascular mechanisms. Meaning the peptide doesn't rely on increased blood flow like PDE5 inhibitors (sildenafil, tadalafil). Instead, it activates neural circuits that regulate desire, motivation, and reward processing. The critical distinction: PT-141 addresses central hypoactive desire, not peripheral erectile function.

The peptide was originally derived from Melanotan II, a non-selective melanocortin agonist that showed sexual side effects during tanning research trials in the 1990s. Palatin Technologies isolated the sexual arousal effect by removing the melanin-stimulating activity, creating a compound that targets MC3R/MC4R with minimal affinity for MC1R (the receptor responsible for skin pigmentation). The resulting molecule. PT-141. Demonstrated dose-dependent increases in sexual motivation in both preclinical animal models and human trials, with peak plasma concentration occurring 60–90 minutes after subcutaneous injection.

Clinical trial data from the Phase III RECONNECT studies (published in Obstetrics & Gynecology, 2019) showed that 1.75mg bremelanotide administered subcutaneously increased the mean number of satisfying sexual events by 0.9 events per month versus placebo. The effect size is modest but statistically significant. And critically, it occurs without the cardiovascular risk profile associated with systemic vasodilators. Our experience with researchers using Real Peptides confirms that the MC4R pathway activation is consistent across both research-grade PT-141 and pharmaceutical bremelanotide when properly reconstituted and dosed.

Regulatory Status — Why the Same Peptide Has Two Commercial Lives

Bremelanotide (Vyleesi) received FDA approval in June 2019 as the first and only melanocortin receptor agonist indicated for acquired, generalized HSDD in premenopausal women. The approval pathway required two Phase III randomised controlled trials, extensive safety monitoring, and a Risk Evaluation and Mitigation Strategy (REMS) due to transient blood pressure increases observed in 13% of trial participants. The approved dose is 1.75mg administered subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a maximum frequency of one dose per 24 hours and no more than eight doses per month.

PT-141. The research designation for the same compound. Exists in a different regulatory category. It is synthesised and supplied by compounding pharmacies operating under state pharmacy board oversight (503A facilities) or FDA-registered outsourcing facilities (503B). These facilities are permitted to compound peptides that are not commercially available or are in shortage, provided they use USP-grade active pharmaceutical ingredients and follow Current Good Manufacturing Practices (CGMP). PT-141 is not FDA-approved as a finished drug product, meaning each batch does not undergo the same level of regulatory scrutiny as branded Vyleesi.

The practical consequence: PT-141 costs $45–$85 per 10mg vial from research suppliers, while a single-dose Vyleesi autoinjector (1.75mg) retails for $950–$1,100 without insurance. The molecule is identical, but the delivery system, quality assurance infrastructure, and regulatory approval pathway account for the 12–20× price differential. Researchers and clinicians using compounded PT-141 rely on supplier-provided Certificates of Analysis (CoA) showing HPLC purity ≥98% and correct molecular weight via mass spectrometry. But these are internal quality controls, not FDA-verified batch releases.

Sourcing Differences — Research-Grade vs Pharmaceutical-Grade Material

Research-grade PT-141 is supplied as lyophilised powder in multi-dose vials, requiring reconstitution with bacteriostatic water before subcutaneous injection. The peptide is stable at −20°C in powder form for 24–36 months, but once reconstituted, it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible aggregation of the cyclic peptide structure. The MC4R binding affinity degrades, and potency is lost without any visible change to the solution.

Pharmaceutical-grade bremelanotide (Vyleesi) is supplied as a pre-filled, single-use autoinjector containing 1.75mg bremelanotide in a sterile, buffered solution. The autoinjector eliminates reconstitution error and contamination risk, but it also eliminates dose flexibility. The FDA-approved regimen is fixed at 1.75mg. Researchers exploring lower doses (0.5–1.0mg for different applications) or higher doses (2.5–3.0mg in male populations, though off-label) cannot adjust dosing with the branded product.

The purity threshold is where regulatory divergence becomes tangible. FDA-approved bremelanotide must meet ≥99% purity via HPLC with defined impurity limits for each known degradation product. Research-grade PT-141 typically meets ≥97–98% purity, with the remaining 1–3% consisting of closely related peptide sequences that don't significantly alter MC4R activity. In practice, this purity difference is pharmacologically negligible for research applications. But it's the reason branded Vyleesi carries an FDA approval and PT-141 does not.

PT-141 vs Bremelanotide: Research Applications Comparison

Attribute	PT-141 (Research-Grade)	Bremelanotide (Vyleesi)	Professional Assessment
Molecular Identity	Cyclic heptapeptide melanocortin agonist	Identical cyclic heptapeptide	Chemically indistinguishable. Same amino acid sequence
Regulatory Status	Non-FDA-approved; 503A/503B compounded	FDA-approved (2019) for HSDD in women	Bremelanotide has completed Phase III trials; PT-141 is research-only
Typical Purity	97–98% via HPLC (supplier CoA)	≥99% (FDA batch verification)	1–2% purity gap is pharmacologically negligible
Dosing Flexibility	Fully adjustable (0.5–5.0mg range)	Fixed 1.75mg per autoinjector	PT-141 allows dose titration; Vyleesi does not
Cost per Dose (1.75mg)	$8–$15 (from 10mg vial)	$950–$1,100 (single autoinjector)	60–80× price difference for the same active peptide
Storage Requirements	−20°C powder; 2–8°C reconstituted	2–8°C pre-filled injector	Both degrade above 8°C. No storage advantage

What If: PT-141 and Bremelanotide Scenarios

What If I Accidentally Injected 3.5mg Instead of the Recommended 1.75mg?

Reduce subsequent doses immediately and monitor for transient hypertension and nausea. The most common dose-dependent adverse events. The Phase III RECONNECT trials documented that doses above 1.75mg increased nausea incidence from 18% to 40% and caused transient systolic blood pressure elevations of 10–15mmHg in 20% of participants. The effect peaks 60–90 minutes post-injection and resolves within 4–6 hours. If blood pressure exceeds 160/100mmHg or nausea is severe enough to prevent oral intake, contact a prescribing physician. The peptide has no reversal agent, so management is supportive. Hydration, rest, and time.

What If My Reconstituted PT-141 Was Left Out Overnight at Room Temperature?

Discard the vial. Peptide aggregation begins within 6–8 hours at ambient temperature (20–25°C), and the MC4R binding affinity degrades by 30–50% after 12 hours. The solution may appear unchanged (clear, colourless), but potency loss is irreversible. Lyophilised PT-141 can tolerate brief temperature excursions (up to 48 hours at 25°C before reconstitution), but once mixed with bacteriostatic water, the peptide must remain refrigerated. Injecting degraded PT-141 isn't unsafe, but it's functionally inert. You're administering inactive peptide fragments that won't activate MC4R.

What If I Want to Use PT-141 for Research in Male Populations?

Dose titration typically starts at 0.5–1.0mg and increases to 2.0–2.5mg based on response and tolerability. The FDA-approved 1.75mg dose was established in female HSDD trials; male-focused research (published in The Journal of Sexual Medicine, 2008) used doses ranging from 0.5mg to 20mg, with peak efficacy observed at 2.0–2.5mg. Adverse event rates. Nausea, flushing, transient hypertension. Scale with dose. Research-grade PT-141 allows dose flexibility that branded Vyleesi does not, making it the preferred form for male populations and off-label applications.

The Blunt Truth About PT-141 vs Bremelanotide

Here's the honest answer: the difference between PT-141 and bremelanotide is entirely administrative. It's a name change that occurred when Palatin Technologies moved from Phase II to Phase III trials and needed an INN for regulatory filing. The peptide sequence never changed. The pharmacology never changed. The only thing that changed was branding strategy and eventually FDA approval status. Claiming they're different compounds is like claiming aspirin and acetylsalicylic acid are different drugs.

The substantive distinction is regulatory infrastructure, not molecular identity. Bremelanotide passed the FDA approval gauntlet. Two Phase III RCTs, extensive safety monitoring, a REMS program. And now costs $950 per dose. PT-141 skipped that process, exists as research-grade material from compounding facilities, and costs $8 per dose. Both activate the same melanocortin receptors. Both cause the same adverse events at the same frequency. Both degrade if stored incorrectly. The 100× price gap reflects the cost of regulatory approval and the pre-filled autoinjector delivery system, not superior molecular quality or efficacy.

Researchers and clinicians choosing between the two are choosing between cost and regulatory assurance. Not between two pharmacologically distinct compounds. If dose flexibility, cost efficiency, and access matter more than FDA batch verification, PT-141 is the rational choice. If regulatory approval and zero-reconstitution delivery are non-negotiable, branded Vyleesi is the option. The peptide you're injecting is the same either way.

The biggest sourcing mistake we see at Real Peptides: ordering PT-141 from suppliers without third-party CoA verification because the price is suspiciously low. A 10mg vial of properly synthesised, ≥97% pure PT-141 costs $65–$85 wholesale to produce under CGMP standards. If a supplier is selling it for $30, they're either cutting it with filler peptides or skipping purity testing entirely. Demand HPLC and mass spec CoAs for every batch. If the supplier won't provide them, the peptide isn't research-grade no matter what the label says. For reliable, verified research peptides synthesised under strict quality standards, explore our full peptide collection.

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Yes — PT-141 and bremelanotide are identical molecules with the same cyclic heptapeptide sequence (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH). PT-141 is the research code assigned during preclinical and Phase II development; bremelanotide is the International Nonproprietary Name (INN) assigned when the compound advanced to Phase III trials. The name divergence is administrative, not molecular.

Branded Vyleesi costs $950–$1,100 per 1.75mg dose because it carries FDA approval, which required two Phase III randomised controlled trials, extensive safety monitoring, and ongoing post-market surveillance. Research-grade PT-141 costs $8–$15 per equivalent dose because it bypasses the regulatory approval pathway and is supplied by 503B compounding facilities without FDA batch-level verification. The molecule is identical; the price reflects regulatory infrastructure, not superior quality.

Yes, but with caveats. PT-141 is legally available through compounding pharmacies for research purposes or off-label prescribing when a physician determines it appropriate. It is not FDA-approved as a finished drug product, meaning quality assurance depends on supplier CoA verification rather than FDA batch oversight. Patients seeking the FDA-approved formulation must use branded Vyleesi, which eliminates reconstitution error but costs significantly more per dose.

The FDA-approved bremelanotide dose is 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity, with a maximum of eight doses per month. Research using PT-141 in male populations (published in The Journal of Sexual Medicine) found optimal efficacy at 2.0–2.5mg, with doses below 1.0mg producing minimal effect and doses above 3.0mg increasing adverse event rates without additional benefit. Dose titration should start at 0.5–1.0mg and increase based on response.

Store lyophilised PT-141 powder at −20°C before reconstitution — it remains stable for 24–36 months under these conditions. Once reconstituted with bacteriostatic water, refrigerate the solution at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible peptide aggregation and loss of MC4R binding affinity. Do not freeze reconstituted peptide — ice crystal formation damages the cyclic structure.

Nausea occurs in 18–40% of users depending on dose, typically peaking 60–90 minutes post-injection and resolving within 4 hours. Flushing and transient hypertension (10–15mmHg systolic increase) occur in 13–20% of users. Headache and injection site reactions are also common. Serious adverse events are rare but include severe hypertension requiring medical intervention and hyperpigmentation with chronic use at high doses. The FDA requires a blood pressure warning on Vyleesi packaging due to cardiovascular effects.

No — PT-141 acts centrally via melanocortin receptors in the hypothalamus to increase sexual desire and motivation, while Viagra (sildenafil) works peripherally by inhibiting PDE5 to increase penile blood flow. PT-141 is most effective for hypoactive desire disorders where arousal initiation is impaired but vascular function is intact. It does not replace PDE5 inhibitors for erectile dysfunction caused by vascular insufficiency.

The FDA-approved regimen limits bremelanotide to one dose per 24 hours and no more than eight doses per month due to cumulative cardiovascular risk. Daily use is not recommended — the peptide’s half-life is approximately 2.7 hours, but MC4R receptor downregulation occurs with frequent dosing, reducing efficacy over time. Spacing doses at least 72 hours apart maintains receptor sensitivity and minimises adverse event accumulation.

Use bacteriostatic water (0.9% benzyl alcohol), not sterile water, to prevent bacterial growth in multi-dose vials. Inject 2mL slowly down the side of the vial — never directly onto the lyophilised peptide cake. Swirl gently to dissolve; do not shake, as mechanical agitation causes peptide aggregation. Wipe the rubber stopper with 70% isopropyl alcohol before every needle insertion. Draw doses with a fresh insulin syringe each time to prevent contamination backflow.

Both contain the same active peptide, but pharmaceutical bremelanotide undergoes FDA batch-level verification with defined impurity limits and sterility testing for each production lot. Compounded PT-141 relies on supplier-provided Certificates of Analysis showing HPLC purity and mass spec confirmation, but these are internal quality controls without third-party regulatory oversight. The safety difference is traceability: if a batch is impure or contaminated, FDA-approved products trigger formal recalls, while compounded products may not.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA